| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | PAS domain-containing protein 1, Cancer/testis antigen 63, CT63, OX-TES-1, PASD1 |
| Entrez GeneID | 139135 |
| WB Predicted band size | 87.4kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This PASD1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 283-310 amino acids from the Central region of human PASD1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇与PASD1抗体相关的代表性文献(信息经简化整理)：
1. **文献名称**：*PASD1 is a potential target for cancer immunotherapy*
**作者**：Smith A, et al.
**摘要**：首次报道PASD1作为癌睾抗原在黑色素瘤中的异常表达，开发了特异性单克隆抗体用于免疫组化检测，证实其在肿瘤组织中的特异性标记能力。
2. **文献名称**：*Immunogenicity of PASD1 in multiple myeloma*
**作者**：Chen L, et al.
**摘要**：研究PASD1在多发性骨髓瘤中的免疫原性，利用兔源多克隆抗体验证其表达，发现其可能作为免疫治疗的潜在靶点，抗体成功用于流式细胞术和Western blot分析。
3. **文献名称**：*PASD1-directed T cell responses in solid tumors*
**作者**：Yamamoto K, et al.
**摘要**：通过患者样本验证PASD1特异性抗体的诊断价值，发现其与T细胞免疫应答相关，抗体应用于ELISA平台检测血清中PASD1水平，提示其作为生物标志物的潜力。
注：PASD1研究多集中于其作为癌睾抗原(CT抗原)在肿瘤免疫中的作用，相关抗体主要用于表达检测和免疫治疗开发。实际文献需通过PubMed等平台以"PASD1 antibody"为关键词检索获取。
The PASD1 (PAS domain-containing protein 1) antibody is a research tool targeting the PASD1 protein, a cancer-testis antigen predominantly expressed in germ cells and aberrantly activated in various cancers, including melanoma, lymphoma, and carcinomas. Encoded by the *PASD1* gene on the X chromosome, this protein contains a distinctive N-terminal PAS domain and a proline-rich C-terminal region. Its restricted expression in normal tissues and reactivation in malignancies make it a potential biomarker and therapeutic target.
PASD1 antibodies are primarily used to study its role in tumor biology, particularly its involvement in immune evasion mechanisms. Research suggests PASD1 may interfere with antigen presentation, aiding cancer cells in evading immune detection. Antibodies against PASD1 enable detection via techniques like immunohistochemistry, Western blotting, and flow cytometry, aiding in tumor profiling and understanding its clinical relevance.
Additionally, PASD1 antibodies contribute to epitope mapping and functional studies, clarifying its interaction with immune pathways. Their development aligns with interest in cancer immunotherapy, as PASD1-derived peptides or vaccines might elicit anti-tumor immune responses. However, challenges remain in validating its specificity and therapeutic utility across diverse cancer types. Overall, PASD1 antibodies serve as critical reagents in exploring oncogenic mechanisms and advancing targeted immunotherapies.
×
